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the FGF receptor signaling pathway is recurrently involved in the leukemogenic processes. oncogenic 
fusions of FGFR1 with various fusion partners were described in myeloid proliferative neoplasms, and 
overexpression and mutations of FGFR3 are common in multiple myeloma. In addition, fibroblast 
growth factors are abundant in the bone marrow, and they were shown to enhance the survival of acute 
myeloid leukemia cells. Here we investigate the effect of FGFR stimulation on pediatric BCP-ALL cells in 
vitro, and search for mutations with deep targeted next-generation sequencing of mutational hotspots 
in FGFR1, FGFR2, and FGFR3. In 481 primary BCP-ALL cases, 28 samples from 19 unique relapsed BCP-
ALL cases, and twelve BCP-ALL cell lines we found that mutations are rare (4/481 = 0.8%, 0/28 and 0/12) 
and do not affect codons which are frequently mutated in other malignancies. However, recombinant 
ligand FGF2 reduced the response to prednisolone in several BCP-ALL cell lines in vitro. We therefore 
conclude that FGFR signaling can contribute to prednisolone resistance in BCP-ALL cells, but that 
activating mutations in this receptor tyrosine kinase family are very rare.
Despite generally excellent outcome for children with pediatric B-cell precursor acute lymphoblastic leukemia 
(BCP-ALL), therapeutic options are limited for refractory or relapsed cases. Small molecule inhibitors of onco-
genic pathways, such as those targeting ABL-, MEK, and JAK kinase families, have shown (pre-)clinical efficacy 
and may be added to chemotherapy in the future. Here we studied the role of fibroblast growth factor receptor 
(FGFR) signaling in pediatric BCP-ALL.
FGFs are not only essential in hematopoietic development, but also influence bone formation by regulating 
expansion and stemness of mesenchymal stromal cells1,2. FGF2 is expressed in the hematopoietic and stromal 
compartments of the bone marrow1. FGFR fusions have been described in atypical myeloproliferative disorders 
which may involve lymphoma or present as BCP-ALL3. High FGFR3 expression is a hallmark of t(4;14)-positive 
multiple myeloma, and activating mutations are recurrently detected in this context4–6. Furthermore, FGFR sign-
aling has been shown to contribute to drug resistance in chronic myeloid leukemia7. Thus, oncogenic FGFR sign-
aling contributes to hematologic malignancies, but so far information on its role in pediatric BCP-ALL is limited. 
We therefore applied a customized targeted sequencing approach for mutational hotspots of FGFR1, FGFR2, and 
FGFR3 and evaluated the effect of recombinant FGF2 on in vitro prednisolone sensitivity in BCP-ALL cell lines.
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Methods
patient material and cell lines. The study comprised children with BCP-ALL with age at diagnosis rang-
ing from 0 to 18 years. Use of excess materials for research purposes has been approved by the Institutional 
Review Board of the University Medical Center Rotterdam on August 2nd, 2004, IRB approval file number MEC 
2004-203. Written informed consent was obtained from parents or legal guardians and studies were conducted 
in accordance with the Declaration of Helsinki. Clinical characteristics were kindly provided by the Dutch 
Childhood Oncology Group (the Hague, Netherlands). Mononuclear cells were isolated using density gradient 
centrifugation with Lymphoprep (Axis Shield, Norway) as previously described8. All samples contained at least 
90% leukemic blasts. Cytogenetic subtypes were determined by karyotype, fluorescence in-situ hybridization 
(FISH), and/or fusion-gene specific PCR. BCR-ABL1-like cases were identified using microarray gene expres-
sion profiling by the means of a 110 probeset classifier9. Leukemic cell lines (697, HAL01, Kasumi-2, LAZ-221, 
MHH-CALL2, MHH-CALL3, MHH-CALL4, Nalm-6, RCH-ACV, Reh, Sup-B15, Tom-1) were obtained from 
the German Collection of Microorganisms and Cell Cultures (DSMZ, Germany) and routinely validated by DNA 
fingerprinting. Unless indicated otherwise, all cell lines were cultured in RPMI-1640 supplemented with 10 to 
20% fetal calf serum and penicillin, streptomycin and fungizone (all Life technologies).
In vitro cytotoxicity assays. The IC50 of prednisolone was determined in an MTS assay for cell lines and 
an MTT assay for primary ALL cells based on a six-step range from 250 to 0.008 µg/mL (Nalm6, 697, RCH-ACV, 
MHH-CALL3) or 1 to 0.003 µg/mL (MHH-CALL2, MHH-CALL4, SupB15, Tom1). For these assays, cells were 
tested for viability in the prednisolone concentration range with or without 50 ng/mL recombinant human FGF2 
(Bio-Rad) and with or without 1 µM AZD4547 (Selleckchem). After four days incubation at 37 °C and 5% CO2, 
cell viability was evaluated using MTS/MTT. IC50-values were calculated as the prednisolone concentration at 
which 50% of cells survived relative to the respective prednisolone-free control of each condition. To avoid redun-
dancies with abundant cytokines in fetal calf serum (FCS), these assays were performed under reduced serum 
conditions (2% FCS for cells usually cultured in 10% FCS, and 4% FCS for those usually cultured with 20% FCS). 
Sensitivity towards AZD4547 was measured similarly, but at normal serum concentrations (10 µM–0.3 nM).
sequencing and code availability. DNA was isolated using Trizol reagent (Life Technologies), or in case of 
three cell lines using the DNeasy Kit (Qiagen). For TruSeq Custom Amplicon sequencing (Illumina, USA), sequenc-
ing libraries were prepared from 100–250 ng genomic DNA. Successful library preparation was confirmed using the 
Labchip GX genomic analyzer (Caliper Life Sciences Benelux N.V., the Netherlands). Samples were then pooled 
equimolarly and sequenced on an Illumina MiSeq in paired-end reads of 250 bp each. Targeted regions and the 
analysis script can be provided upon request. Next, sequence reads were aligned to the 1000 genomes human ref-
erence sequences (version b37, GATK resource bundle, Broad Institute, USA) using BWA v0.7.1010 and GATK 
indel realigner v.3.3-0. Single nucleotide variants were called with Freebayes v0.9.18–2411, Varscan v.2.3.712, Bcftools 
v1.013, and GATK v3.3-014. The resulting variant call format files were annotated using snpEff and snpSift v.4.1a15 
and dbNSFP v.2.716. For reliable detection of high-confidence mutations, variants were filtered based on several 
criteria: For each sample, variants were excluded if they were reported by only one caller, coverage was <100 reads, 
or <20 reads supported the variant allele. Also variants likely to result from amplification or sequencing errors were 
excluded, i.e. those that occur repeatedly (n ≥10) but in a low fraction of reads within all samples (variant allele 
frequency (VAF) within each sample <2%) and those with an unequal distribution between runs. Furthermore, 
variants were only considered if they were non-synonymous, unlikely to be germline variants and not known SNPs. 
Mutational hotspots are indicated in Fig. 1c and were obtained from literature and the COSMIC database (v79, 
released 14th November 2016)6. All data and analysis code can be made available upon request.
Results
FGF2 stimulation reduces prednisolone sensitivity in a subset of BCP-ALL cells. FGF2-mediated 
signaling through FGFR3 has been implicated in therapy resistance in AML7. We therefore evaluated the resist-
ance-inducing effect of FGF2 on prednisolone cytotoxicity, a core component of ALL chemotherapy, using in vitro 
drug sensitivity assays. To avoid redundancies with abundant cytokines in fetal calf serum (FCS), these assays were 
performed under reduced serum conditions (2% FCS for cells usually cultured in 10% FCS, and 4% FCS for cells 
usually cultured with 20% FCS). The IC50 of prednisolone was determined in an MTS assay for eight BCP-ALL cell 
lines see also Supplemental Fig. 1). In five of the eight tested cell lines exposure to 50 ng/mL recombinant human 
FGF2 (Bio-Rad, USA) resulted in on average two- to three-fold higher IC50-values for prednisolone (Nalm6, 697, 
RCH-ACV, Tom1, and MHH-CALL3, Fig. 1a). The resistance induced by the ligand FGF2 was reversed by exposure 
to 1 µM of FGFR inhibitor AZD4547. AZD4547 as single agent reduced viability in BCP-ALL cell lines only at higher 
concentrations (5 to 20 µM, Fig. 1b), except for Nalm6 and RCH-ACV cell line (20–40% cell death induced at 1 µM 
AZD4547). The prednisolone IC50-values were corrected for the cytotoxic effect of AZD4547 as single agent and 
therefore reflect the synergistic effect of this FGFR inhibitor on the response to prednisolone.
Absence of know oncogenic mutations in the genes FGFR1, -2, and -3. Using the TruSeq Custom 
Amplicon technique as previously described (ref.17 and Supplementary information), we screened for mutations 
in 481 primary BCP-ALL cases at initial diagnosis, in 28 BCP-ALL relapse samples (representing 19 unique 
patients) and in twelve BCP-ALL cell lines. The regions covered by the custom amplicons are indicated in Fig. 1c, 
and were selected to cover regions of functional relevance (e.g. the tyrosine kinase domain and transmembrane 
domain) and previously reported mutational hotspots of FGFR1, FGFR2, and FGFR3 (Fig. 1c, hotspots are indi-
cated below each gene). In 481 unique patients we found 4 non-synonymous, likely somatic FGFR variants. 
These variants were detected in samples taken at initial diagnosis, one FGFR1 (D129A) mutation, two FGFR2 
mutations (V274I and D522N), and one FGFR3 (F384I) mutation (Fig. 1c, above gene schematics). No mutations 
www.nature.com/scientificreports/
3Scientific RepoRts |          (2019) 9:1875  | https://doi.org/10.1038/s41598-018-38169-z
Figure 1. FGFR signaling is not essential in pediatric BCP-ALL cells, but can reduce prednisolone sensitivity. 
(a) Effect of 50 ng/mL recombinant human FGF2 on ex vivo response to prednisolone in BCP-ALL cell lines and 
reversal by the FGFR-inhibitor AZD4547 (1 µM). Left panels: prednisolone IC50-concentrations are depicted 
for each cell line. IC50-values for the combination of FGF2 and AZD4547 were calculated after correction 
for cytotoxic effects of FGF2 and AZD4547 as single agents on leukemic cell survival (see also panel (b); 
corresponding dose-response curves are shown in Supplemental Fig. 1b). Bars represent the mean ± SEM of 
Nalm6 (n = 3), 697 (n = 3), RCH-ACV (n = 3), SupB15 (n = 3), Tom1 (n = 2), MHH-CALL2 (n = 4), MHH-
CALL3 (n = 1), and MHH-CALL4 (n = 4). Right panel: mean fold change of prednisolone IC50-values in 
FGF2-responsive cell lines (Nalm6, 697, RCH-ACV, Tom1, and MHH-CALL3), **p = 0.0012 by Wilcoxon 
matched pairs test. (b) Ex vivo response of BCP-ALL cell lines to the FGFR-inhibitor AZD4547. Dashed 
line: 50% survival; Cytogenetic subtypes are indicated in brackets: DUX4: DUX4-rearranged leukemia, TP: 
TCF3-PBX1-rearranged, BA: BCR-ABL1-rearranged, HD: high hyperdiploid karyotype, CRLF2: high CRLF2 
expression, ER: ETV6-RUNX1-rearranged. (c) Schematic representation of protein domains of the FGFR 
genes and the observed variants. Black bars indicate the regions covered by targeted amplicon sequencing. 
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were detected in the B-cell precursor ALL cell line panel or in the 28 relapse samples. The FGFR1 D129A and 
FGFR2 V274I mutations were predicted to be damaging to the protein function by the SIFT, Polyphen, LRT, and 
MutationTaster tools18. However, it is important to note that these prediction tools were trained to detect delete-
rious mutations, and activating mutations could be predicted as benign. Variant allele frequencies (VAF) varied, 
with 8.4% for the FGFR2 D522N variant, 28.5% for the FGFR1 D129A variant, 40.8% for the FGFR2 V274I 
variant, and 52.9% for the FGFR3 F384I variant. None of these mutations represents a frequently observed path-
ogenic mutation, such as those reported in multiple myeloma, according to literature and the COSMIC database 
(v79 released 14-Nov-16, indicated below each gene in Fig. 1c)19. Their phenotypic effect is unclear, however, all 
mutations locate within functional domains of the FGFR proteins (colored boxes).
FGFR variants occurred in two ETV6-RUNX1-rearranged cases, one BCR-ABL1-like with a JAK2 translo-
cation, and one high hyperdiploid, and high white blood cell count (≥50 cells/nL) was found in two out of four 
cases, high minimal residual disease (percentage blasts in bone marrow on day 33 of therapy ≥0.1%) in one out 
of three cases (Supplemental Table 1 one case without data available). The JAK2-translocated case harboring an 
FGFR1 D129A mutation experienced a relapse 1 year after diagnosis. In conclusion, FGFR variants occurred 
in various subtypes and patients did not consistently present with poor or good prognostic factors. Notably, 
the FGFR inhibitor was not effective in primary leukemic cells carrying the D129A point mutation in FGFR1 
(Fig. 1d). Unfortunately no viable leukemic cells were available for other mutated BCP-ALL cases.
Discussion
Here we screened 481 pediatric BCP-ALL cases at initial diagnosis, 19 relapse BCP-ALL cases, and 12 BCP-ALL 
cell lines for variants in FGFR1, FGFR2, and FGFR3. We found a low frequency of variants among patients at 
initial diagnosis, and no variants in the relapse cohort or in cell lines. These data indicate that FGFR mutations are 
very rare in pediatric BCP-ALL. Due to the low incidence and a small relapse cohort, it remains to be determined 
whether these rare mutations have an effect on the clinical prognosis. With the limited data available, we conclude 
that this does not seem to be the case.
The observed mutations are located within functional domains of the FGFR proteins: The FGFR1 D129A 
mutation affects the so-called acid box of the receptor, which has been shown to be essential for auto-inhibition 
and interaction with adhesion molecules20,21. The FGFR2 mutations V274I and D522N locate in the 
ligand-binding immunoglobulin-like (Ig) domain and the tyrosine kinase domain (TKD), respectively. They 
might therefore alter ligand-binding and kinase activation. Last, the FGFR3 F384I mutation is located in the 
transmembrane domain (TMD), which is frequently affected by mutations that cause aberrant receptor dimeri-
zation (e.g. by insertion of a cysteine). Of note, a rare F384L SNP at the same location has been reported and was 
also found in our screen. No functional consequences have been reported for this SNP, and the high similarity 
between leucine and isoleucine suggests no effect of the F384I variant on FGFR3 function22.
Given the previous implications of FGFR signaling in resistance, we evaluated its effect on the efficacy of predniso-
lone in vitro7. Our data indicate that the ligand FGF2 induced resistance to glucocorticoids which could be reversed by 
inhibition of FGFR. Traer et al. suggested that reactivation of the MAPK pathway by FGFR3 accounts for FGF-mediated 
resistance of BCR-ABL1-rearranged chronic myeloid leukemia cells to imatinib. In line with this observation, we and 
others have previously shown that MAPK pathway mediated signaling can also increase resistance towards predniso-
lone23–25. Downstream-located MAPK signaling may therefore be the mediator of FGF-induced glucocorticoid resist-
ance, and could serve as therapeutic target for sensitization towards prednisolone in resistant cases.
Taken together, our data demonstrates that FGFR-activating lesions are rare in newly diagnosed pediatric 
BCP-ALL, and were not enriched at the time of relapse. Activating mutations which are frequently observed 
in multiple myeloma or solid cancers were not observed in 481 newly diagnosed nor in 19 relapsed BCP-ALL 
cases19. As FGFR activating mutations were virtually absent, FGF2 ligand-mediated activation of FGFR-signaling 
may be more relevant for the sensitivity of leukemic cells to prednisolone.
Data Availability
Data can be made available upon request.
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